Understanding the nature of renal disease progression

Kidney International

Volumn 51, Issue 1, 1997, Pages 2-15

  Remuzzi, Giuseppe ^a,b   Ruggenenti, Piero ^a   Benigni, Ariela ^a  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW;

EID: 0031042356     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1997.2     Document Type: Article

References (168)

1. BRENNER BM, MEYER TW, HOSTETTER TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
2. HOSTETTER TH, OLSON JL, RENNKE HG, VENKATACHALAM MA, BRENNER BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 241:F85-F93, 1981
3. KLAHR S, SCHREINER G, ICHIKAWA I: The progression of renal disease. N Engl J Med 318:1657-1666, 1988
4. REMUZZI G, BERTANI T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38:384-394, 1990
5. ANDERSON S, MEYER TW, RENNKE HG, BRENNER BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76:612-619, 1985
6. ZATZ R, DUNN BR, MEYER TW, ANDERSON S, RENNKE HR, BRENNER BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
7. ANDERSON S, RENNKE HG, GARCIA DL, BRENNER BM: Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36:526-536, 1989
8. HOSTETTER TH, MEYER TW, RENNKE HG, BRENNER BM: Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int 30:509-517, 1986
9. ANDERSON S, RENNKE HG, BRENNER BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000, 1986
10. MEYER TW, ANDERSON S, RENNKE HG, BRENNER BM: Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 31:752-759, 1987
11. EDDY AA, MCCULLOCH L, LIU E, ADAMS J: A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome. Am J Pathol 138:1111-1123, 1991
12. MORI H, YAMASHITA H, NAKANISHI C, KOIZUMI K, MAKINO S, KISHIMOTO Y, HAYASHI Y: Proteinuria induced by transplantable rat pituitary tumor MtT SA5. Model for homologous protein overload proteinuria. Lab Invest 54:636-644, 1986
13. MAGIL AB: Tubulointerstitial lesions in human membranous glomerulonephritis: Relationship to proteinuria. Am J Kidney Dis 25:375-379, 1995
14. BERTANI T, CUTILLO F, ZOJA C, BROGGINI M, REMUZZI G: Tubulointerstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 30:488-496, 1986
15. REMUZZI G: Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. Curr Opin Nephrol Hypertens 4:339-342, 1995
16. APPERLOO AJ, DE ZEEUW D, DE JONG PE: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 45(Suppl 45):S174-S178, 1994
17. DEEN WM, BRIDGES CR, BRENNER BM, MYERS BD: Heteroporous model of glomerular size selectivity: Application to normal and nephrotic humans. Am J Physiol 249:F374-F389, 1985
18. REMUZZI A, BATTAGLIA C, ROSSI L, ZOJA C, REMUZZI G: Glomerular size selectivity in nephrotic rats exposed to diets with different protein content. Am J Physiol 253:F318-F327, 1987
19. MYERS BD, NELSON RG, WILLIAMS GW, BENNETT PH, HARDY SA, BERG RL, LOON N, KNOWLER WC, MITCH WE: Glomerular function in Pima Indians with noninsulin-dependent diabetes mellitus of recent onset. J Clin Invest 88:524-530, 1991
20. MYERS BD, GUASCH A: Mechanisms of massive proteinuria. J Nephrol 7:254-260, 1994
21. REMUZZI A: Mathematical description of transport of water and macromolecules through the glomerular capillary wall. Curr Opin Nephrol Hypertens 4:343-348, 1995
22. YOSHIOKA T, MITARAI T, KON V, DEEN WM, RENNKE HG, ICHIKAWA I: Role for angiotensin Il in an overt functional proteinuria. Kidney Int 30:538-545, 1986
23. YOSHIOKA T, RENNKE HG, SALANT DJ, DEEN WM, ICHIKAWA I: Role of abnormally high transmural pressure in the permselectivity defect of glomerular capillary wall: A study in early passive Heymann nephritis. Circ Res 61:531-538, 1987
24. LEE LK, MEYER TW, POLLOCK AS, LOVETT DH: Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 96:953-964, 1995
25. IORDACHE BE, IMBERTI O, FOGLIENI C, REMUZZI G, BERTANI T, REMUZZI A: Effects of angiotensin-converting enzyme inhibition on glomerular capillary wall ultrastructure in MWF/Ztm rats. J Am Soc Nephrol 5:1378-1384, 1994
26. NAKAMURA T, TAKAHASHI T, FUKUI M, EBIHARA I, OSADA S, TOMINO Y, KOIDE H: Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol 5:1492-1497, 1995
27. RUIZ-ORTEGA M, GONZALEZ S, SERON D, CONDOM E, BUSTOS C, LARGO R, GONZALEZ E, ORTIZ A, EGIDO J: ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 48:1778-1791, 1995
28. MORELLI E, LOON N, MEYER T, PETERS W, MYERS BD: Effects of convertine-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 39:76-82, 1990
29. REMUZZI A, RUGGENENTI P, MOSCONI L, PATA V, VIBERTI G, REMUZZI G: Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J Nephrol 6:36-43, 1993
30. REMUZZI A, PERTICUCCI E, RUGGENENTI P, MOSCONI L, LIMONTA M, REMUZZI G: Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 39:1267-1273, 1991
31. CAMERON JS: Clinicopathologic correlations in glomerular disease, in Kidney Disease - Present Status, edited by SOMMER W, Baltimore, Williams & Wilkins, 1979, pp 76
32. VELOSA JA, HOLLEY KE, TORRES VE, OFFORD KP: Significance of proteinuria on the outcome of renal function in patients with focal glomerulosclerosis. Mayo Clin Proc 58:568-577, 1983
33. MALLICK NP, SHORT CD, HUNT LP: How far since Ellis? Nephron 46:113-124, 1987
34. WEHRMANN M, BOHLE A, BOGENSCHUTZ O, EISSELE R, FREISLEDERER A, OHLSCHLEGEL C, SCHUMM G, BATZ C, GARTNER H-V: Long-term prognosis of chronic idiopathic membranous glomerulonephritis. Clin Nephrol 31:67-76, 1989
35. RISDON RA, SLOPER JC, DE WARDENER HE: Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet II:363-366, 1968
36. SCHAINUCK LI, STRIKER GE, CUTLER RE, BENDITT EP: Structural-functional correlations in renal disease II. The correlations. Hum Pathol 1:631-641, 1970
37. CAMERON JS, TURNER DR, OGG, CS, CHANTLER C, WILLIAMS DG: The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 10:213-218, 1978
38. CAMERON JS, TURNER DR, HEATON J, WILLIAMS DG, OGG CS, CHANTLER C, HAYCOCK GB, HICKS J: Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 74:175-192, 1983
39. ROSSING, P, HOMMEL E, SMIDT UM, PARVING H: Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42:715-719, 1993
40. WATKINS PJ, BLAINEY JD, BREWER DB, FITZGERALD MG, MALINS JM, O'SULLIVAN DJ, PINTO JA: The natural history of diabetic renal disease. Q J Med 41:437-456, 1972
41. GALL M-A, NIELSEN FS, SMIDT UM, PARVING H-H: The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. (abstract) Diabetologia 35(Suppl 1):A147, 1992
42. LEBOVITZ HE, WIEGMANN TB, CNAAN A, SHAHINFAR S, SICA DA, BROADSTONE V, SCHWARTZ SL, MENGEL MC, SEGAL R, VERSAGGI JA, BOLTON WK: Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int 45(Suppl 45):S150-S155, 1994
43. RUILOPE LM, ALCAZAR JM, HERNANDEZ E, MORENO F, MARTINEZ MA, RODICIO JL: Does an adequate control of blood pressure protect the kidney in essential hypertension? J Hypertens 8:525-531, 1990
44. GRUPPO ITALIANO STUDI EPIDEMIOLOGICI IN NEFROLOGIA (GISEN): A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. J Nephrol 3:193-202, 1991
45. RUGGENENTI P, PERNA A, LANZONI M, VIGANÒ GL, REMUZZI G: In non diabetic chronic nephropathies urinary protein excretion rate-segregates subgroups of patients with predictably different rates of GFR decline (DGFR) (abstract). J Am Soc Nephrol 6:401, 1995
46. SCHWEGLER JS, HEPPELMANN B, MILDENBERGER S, SILBERNAGL S: Receptor-mediated endocytosis of albumin in cultured opossum kidney cells: A model for proximal tubular protein reabsorption. Pflügers Arch 418:383-392, 1991
47. WALL DA, MAACK T: Endocytic uptake, transport, and catabolism of proteins by epithelial cells. Am J Physiol 248:C12-C20, 1985
48. MAACK T: Changes in the activity of acid hydrolases during renal reabsorption of lysozyme. J Cell Biol 35:268-273, 1967
49. MAACK T, PARK CH, CAMARGO MJF: Renal filtration, transport, and metabolism of proteins, in The Kidney: Physiology and Pathophysiology, edited by SELDIN DW, GIEBISCH G, New York, Raven Press, 1985, pp 1773-1803
50. ZAGER RA, SCHIMPF BA, BREDL CR, GMUR DJ: Inorganic iron effects on in vitro hypoxic proximal tubular cell injury. J Clin Invest 91:702-708, 1993
51. HARRIS DCH, CHEN L, TAY C, CHEN J, NANKIVELL BJ: Cytotoxicity of reabsorbed protein in proximal tubule (PT) by peroxidation. (abstract) J Am Soc Nephrol 5:944, 1994
52. ALFREY AC, FROMENT DH, HAMMOND WS: Role of iron in tubulointerstilial injury in nephrotoxic serum nephritis. Kidney Int 36:753-759, 1989
53. HOWARD RL, BUDDINGTON B, ALFREY AC: Urinary albumin excretion, transferrin and iron excretion in diabetic patients. Kidney Int 40:923-926, 1991
54. OLBRICHT CJ, CANNON JK, GARG LC, TISHER CC: Activities of cathepsin B and L in isolated nephron segments from proteinuric and non proteinuric rats. Am J Physiol 250:F1055-F1062, 1986
55. FELD S, HIRSCHBERG R, ARTISHEVSKY A, NAST C, ADLER S: Insulin-like growth factor 1 induces mesangial proliferation and increases mRNA and secretion of collagen. Kidney Int 48:45-51, 1995
56. BAXTER R, MARTIN J: Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: Determination by reconstitution and affinity-labeling. Proc Natl Acad Sci USA 86:6898-6902, 1989
57. FRYSTYK J, SKJAERBAEK C, DINESEN B, ORSKOV H: Free insulin like growth factor (IGF-I and IGF-II) in human serum. FEBS Lett 348:185-191, 1994
58. HIRSCHBERG R: Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulo-interstitial lesions. J Clin Invest (in press)
59. HIRSCHBERG R, DING, H, WANNER C: Effects of insulin-like growth factor I on phosphate transport in cultured proximal tubule cells. J Lab Clin Med 126:428-434, 1995
60. HAMMERMAN MR, ROGERS S: Distribution of IGF receptors in the plasma membrane of proximal tubular cells. Am J Physiol 253:F841-F847, 1987
61. HAVERTY TP, KELLY CJ, HINES WH, AMENTA PS, WATANABE M, HARPER RA, KEFALIDES NA, NEILSON EG: Characterization of a renal tubular epithelial cell line which secretes the autologous target antigen of autoimmune experimental interstitial nephritis. J Cell Biol 107:1359-1368, 1988
62. ZIYADEH F, JIN Y, GUO J, ERICKSEN M, SHARMA K: Up-regulation of type II TGF-β receptor mRNA by IGF-1 in proximal tubular cells: Role in diabetic renal hypertrophy. (abstract) J Am Soc Nephrol 6:1053, 1995
63. HARRIS DCH, CHEN J: Monocyte chemoattractant protein-1 (MCP-1) mRNA expression in response to protein in rat proximal tubule cells in culture. (abstract) J Am Soc Nephrol 6:1015, 1995
64. OPPENHEIM JJ, ZACHARIAE COC, MUKAIDA N, MATSUSHIMA K: Properties of the novel proinflammatory supergene "intererine" cytokine family. Annu Rev Immunol 9:617-648, 1991
65. YOSHIMURA T, ROBINSON EA, TANAKA S, APPELLA E, LEONARD EJ: Purification and amino acid analysis of two human monocyte chemoattractants produced by pythohemagglutin-stimulated human blood mononuclear leukocytes. J Immunol 142:1956-1962, 1989
66. PRODJOSUDJADI W, GERRITSMA JSJ, KLAR-MOMAMAD N, GERRITSEN AF, BRUIJN JA, DAHA MR, VAN ES LA: Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int 48:1477-1486, 1995
67. LEONARD EJ, YOSHIMURA T: Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 11:97-101, 1990
68. CARK MW, ROTH SJ, LUTHER E, ROSE SS, SPRINGER TA: Monocyte chemoattractant protein-1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 91:3652-3656, 1994
69. EDDY AA: Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol 135:719-733, 1989
70. EDDY AA: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 5:1273-1287, 1994
71. ROVIN BH, DICKERSON JA, TAN LC, HEBERT CA: Activation of nuclear factor-κB correlates with MCP-1 expression by human mesangial cells. Kidney Int 48:1263-1271, 1995
72. KAKIZAKI Y, SUGIMOTO K, WAGA S, TANAKA H, YOKOYAMA M: Transcription factors NF-κB and AP-1 regulate gene expression of monocyte chemoattractant protein-1 (MCP-1) by bovine glomerular endothelial cells (GEN). (abstract) J Am Soc Nephrol 6:833, 1995
73. BEG AA, FINCO TS, NANTERMET PV, BALDWIN AS JR: Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκBa: A mechanism for NF-κB activation. Mol Cell Biol 13:3301-3310, 1993
74. BROWN K, PARK S, KANNO T, FRANZOSO G, SIEBENLIST U: Mutual regulation of the transcriptional activator NF-κB and its inhibitor, IκB-a. Proc Natl Acad Sci USA 90:2532-2536, 1993
75. PAHL HL, BAEUERLE PA: A novel signal transduction pathway from the endoplasmic reticulum to the nucleus is mediated by transcription factor NF-κB. EMBO J 14:2580-2588, 1995
76. EDDY AA, GIACHELLI CM: Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 47:1546-1557, 1995
77. BUTLER WT: The nature and significance of osteopontin. Connect Tissue Res 23:123-136, 1989
78. PICHLER R, GIACHELLI CM, LOMBARDI D, PIPPIN J, GORDON K, ALPERS CE, SCHWARTZ SM, JOHNSON RJ: Tubulointerstitial disease in glomerulonephritis: Potential role of osteopontin (uropontin). Am J Pathol 144:915-926, 1994
79. GIACHELLI CM, PICHLER R, LOMBARDI D, DENHARDT DT, ALPERS C, SCHWARTZ S, JOHNSON RJ: Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 45:515-524, 1994
80. MAIN IW, NIKOLIC-PATERSON DJ, ATKINS RC: T cells and macrophages and their role in renal injury. Semin Nephrol 12:395-407, 1992
81. DANOFF TM, LALLEY PA, CHANG YS, HEEGER PS, NEILSON EG: Cloning, genomic organization, and chromosomal localization of the Scya5 gene encoding the murine chemokine RANTES. J Immunol 152:1182-1189, 1994
82. HEEGER P, WOLF G, MEYERS C, SUN MJ, O'FARRELL SC, KRENSKY AM, NEILSON EG: Isolation and characterization of cDNA from renal tubular epithelium encoding murine Rantes. Kidney Int 41: 220-225, 1992
83. INOUE A, YANAGISAWA M, KIMURA S, KASUYA Y, MIYAUCHI T, GOTO K, MASAKI T: The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86:2863-2867, 1989
84. BENIGNI A, REMUZZI G: Endothelin in the progressive renal disease of glomerulopathies. Miner Electrol Metab 21:283-291, 1995
85. YOSHIMURA A, IWASAKI S, INUI K, IDEURA T, KOSHIKAWA S, YANAGISAWA M, MASAKI T: Endothelin-1 and endothelin B type receptor are induced in mesangial proliferative nephritis in the rat. Kidney Int 48:1290-1297, 1995
86. NAKAMURA T, EBIHARA I, FUKUI M, OSADA S, TOMINO Y, MASAKI T, GOTO K, FURUICHI Y, KOIDE H: Modulation of glomerular endothelin and endothelin receptor gene expression in aminonucleoside-induced nephrosis. J Am Soc Nephrol 5:1585-1590, 1995
87. NAKAMURA T, EBIHARA I, FUKUI M, OSADA S, TOMINO Y, MASAKI T, GOTO K, FURUICHI Y, KOIDE H: Renal expression of mRNAs for endothelin-1. endothelin-3 and endothelin receptors in NZB/W F1 mice. Renal Physiol Biochem 16:233-243, 1993
88. NAKAMURA T, EBIHARA I, FUKUI M, TOMINO Y, KOIDE H: Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 44:895-899, 1995
89. LEE M-E, TEMIZER DH, CLIFFORD JA, QUERTERMOUS T: Cloning of the GATA-binding protein that regulates endothelin-1 gene expression in endothelial cells. J Biol Chem 266:16188-16192, 1991
90. DORFMAN DM, WILSON DB, BRUNS G, ORKIN SH: Human transcription factor GATA-2. J Biol Chem 267:1279-1285, 1992
91. MARSEN TA, SCHRAMEK H, DUNN MJ: Renal actions of endothelin: Linking cellular signaling pathways to kidney disease. Kidney Int 45:336-344, 1994
92. LEE M-E, DHADLY MS, TEMIZER DH, CLIFFORD JA, YOSHIZUMI M, QUERTERMOUS T: Regulation of endothelin-1 gene expression by fos and jun. J Biol Chem 266:19034-19039, 1991
93. KOHAN DE: Endothelin synthesis by rat tubule cells. Am J Physiol 261:F221-F226, 1991
94. KOHAN DE, PADILLA E: Endothelin-1 is an autoerinc factor in rat inner medullary collecting ducts. Am J Physiol 32:F607-F612, 1942
95. ZOJA C, MORIGI M, FIGLIUZZI M, BRUZZI I, OLDROYD S, BENIGNI A. RONCO PM, REMUZZI G: Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 26:934-941, 1995
96. ONG ACM, JOWETT TP, FIRTH JD, BURTON S, KITAMURA M, FINE LG: A new paracrine loop implicated in human tubulo-interstitial fibrosis: Tubular-derived endothelins modulate renal interstitial fibroblast function, (abstract) J Am Soc Nephrol 4:473, 1993
97. CHEN XM, YU LF, ZENG Q: Production of endothelin (ET-1) in kidney tubular cell (LLC-PK1) induced by extracellular matrix (ECM). ISN XIII Congress, Madrid, July 2-6, Theme VII, 1995, p 299 (abstract)
98. ACHMAD T, RAO G: Chemotaxis of human blood monocytes towards endothelin-1 and the influence of calcium channel blockers. Biochem Biophys Res Commun 189:994-1000, 1992
99. HELSET E, SILDNES T, SELJELID R, KONOPSKI ZS: Endothelin-1 stimulates human monocytes in vitro to release TNF-α, IL-1β and IL-6. Mediators of Inflammation 2:417-422, 1993
100. ORISIO S, BENIGNI A, BRUZZI I, CORNA D, PERICO N, ZOJA C. BENATTI L, REMUZZI G: Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 43:354-358, 1993
101. ZOJA C, CORNA D, BRUZZI I, FOGLIENI C, BERTANI T, REMUZZI G, BENIGNI A: Passive Heymann nephritis: Evidence that angiotensin converting enzyme inhibition reduces proteinuria and retards renal structural injury. Exp Nephrol 4:213-221, 1996
102. THEURING F, SCHMAGER F, THONE-REINICKE C, CHOTZEN S, QUERTERMOUS T, SCHLEUNING W-D, HOCHER B: Transgenic mice in endothelin research. Fourth International Conference on Endothelin. London, April 23-26, 1995, p 146 (abstract)
103. HOCHER B, LIEFELDT L, THONE-REINEKE C, ORZECHOWSKI H, DISTLER A, BAUER C, PAUL M: Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension 28:196-201, 1996
104. TAKEDA M, KOMEYAMA T, TSUTSUI T, MIZUSAWA T, KATAYAMA Y, GO H, TAMAKI M, HATANO A: Changes in urinary excretion of endothelin-1-like immunoreactivity before and after unilateral nephrectomy in humans. Nephron 67:180-184, 1994
105. OHTA K, HIRATA Y, SHICHIRI M, KANNO K, EMORI T, TOMITA K, MARUMO F: Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 39:307-311, 1991
106. MURER L, ZACCHELLO G, BASSO G, SCARPA A, MONTINI G, CHIOZZA ML, ZACCHELLO F: Immunohistochemical distribution of endothelin in biopsies of pediatric nephrotic syndrome. Am J Nephrol 14:157-161, 1994
107. LIU X-H, OLDROYD S, ABBATE M, CORNA D, ZOJA C, BENIGNI A, REMUZZI G: Combined administration of ACE inhibitor (ACEi) and angiotensin II receptor antagonist (All ra) normalizes excessive renal endothelin (ET-1) in rats with passive Heymann nephritis, (abstract) J Am Soc Nephrol 6:874, 1995
108. ZOJA C, CORNA D, FACCHINETTI D, MAFFI R, LUZZANA E, BERTANI T, REMUZZI G: Combining ACE inhibition and angiotensin II (All) receptor blocking stop renal disease progression in experimental membranous nephropathy (MN). (abstract) J Am Soc Nephrol 6:860, 1995
109. SPECTOR AA: Plasma albumin as a lipoprotein, in Biochemistry and Biology of Plasma Lipoproteins. Volume II: The Biochemistry of Disease, edited by SCANU AM, SPECTOR AA, New York, Marcel Dekker, 1986, pp 247-279
110. HUMES HD, NGUYEN VD, CIESLINSKI DA, MESSANA JM: The role of free fatty acids in hypoxia-induced injury to renal proximal tubule cells. Am J Physiol 256:F688-F696, 1989
111. GHERARDI E, CALANDRA S: Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside. Biochim Biophys Acta 710:188-196, 1981
112. KEES-FOLTS D, SADOW JL, SCHREINER GF: Tubular catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int 45:1697-1709, 1994
113. SCHREINER GF: Renal toxicity of albumin and other lipoproteins. Curr Opin Nephrol Hyperten 4:369-373, 1995
114. 99mTc and urinary ammonia: Effects of proteinuria. Miner Electrol Metab 18:108-112, 1992
115. NATH KA, HOSTETTER MK, HOSTETTER TH: Pathophysiology of chronic tubulointerstitial disease in rats: Interactions of dietary acid load, ammonia and complement component C3. J Clin Invest 76:667-675, 1985
116. JACKLE I, GUNTHER H, VON GISE H, ALT JM, BOHLE A, STOLTE H: Kidney function and protein excretion in relation to pathomorphology of glomerular diseases. Contrib Nephrol 68:128-135, 1988
117. BOHLE A, VON GISE H, MAIKENSEN-HAEN S, STARK-JAKOB B: The obliteration of the post-glomerular capillaries and its influence upon the function of both glomeruli and tubuli functional interpretation of morphologic findings. Klin Wochenschr 59:1043-1051, 1981
118. HEPTINSTALL RH: Chronic glomerulonephritis, end-stage kidney and visceral changes in chronic renal failure, in Pathology of the Kidney (3rd ed), edited by HEPTINSTALL RH. Boston, Little, Brown and Co, 1983, pp 601-636
119. ZAMLAUSKI-TUCKER MJ, VAN LIEW JB, GOLDINGER J, NOBLE B: Persistent proximal tubule dysfunction late in Heymann nephritis. Kidney Int 37:1536-1542, 1990
120. HUTCHISON FN, KAYSEN GA: Albuminuria causes lysozymuria in rats with Heymann nephritis. Kidney Int 33:787-791, 1988
121. HARRISON JF, LUNT GS, SCOTT P, BLAINEY JD: Urinary lysozyme, ribonuclease, and low-molecular-weight protein in renal disease. Lancet I:371-375, 1968
122. ANDERSON S, DIAMOND JR, KARNOVSKY MJ, BRENNER BM: Mechanisms underlying transition from acute glomerular injury late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 82:1757-1768, 1988
123. DIAMOND JR, ANDERSON S: Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Am J Pathol 137:1323-1332, 1990
124. BERTANI T, ZOJA C, ABBATE M, ROSSINI M, REMUZZI G: Age-related nephropathy and proteinuria in rats with intact kidneys exposed to diets with different protein contents. Lab Invest 60:196-204, 1989
125. WEHRMANN M, BOHLE A, HELD H, SCHUMM G, KENDZIORRA H, PRESSLER H: Long-term prognosis of focal sclerosis glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 33:115-122, 1990
126. MACKENSEN-HAEN R, EISSELE R, BOHLE A: Contribution on the correlation between morphometric parameters gained from the renal cortex and renal function in IgA nephritis. Lab Invest 59:239-244, 1988
127. SCHMITT H, CAVALCANTI DE OLIVEIRA V, BOHLE A: Tubulo-interstitial alterations in type I membranoproliferative glomerulonephrilis. An investigation of 259 cases. Pathol Res Pract 182:6-10, 1987
128. MCDELL JR, HAYS RC, GUGGENHEIM SJ, STEIGERWALD JC: Tubulointerstitial renal disease in systemic lupus erythematosus. Arch Intern Med 145:1996-1999, 1985
129. BOHLE A, WEHRMANN M, BOGENSCHUTZ O, BATZ C, MULLER CA, MULLER GA: The pathogenesis of chronic renal failure in diabetic nephropathy: Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 187:251-259, 1991
130. MACKENSEN-HAEN S, BOHLE A, CHRISTENSEN J, WEHRMANN M, KENDZIORRA H, KOKOT F: The consequences for renal function of widening of the interstitium and changes in the tubular epithelium of the renal cortex and outer medulla in various renal diseases. Clin Nephrol 37:70-77, 1992
131. HOWIE AJ, GUNSON BK, SPARKE J: Morphometric correlates of renal excretory function. J Pathol 160:245-253, 1990
132. MARCUSSEN N: Atubular glomeruli and the structural basis for chronic renal failure. Lab Invest 66:265-284, 1992
133. BERTANI T, POGGI A, POZZONI R, DELAINI F, SACCHI G, THOUA Y, MECCA G, REMUZZI G, DONATI MB: Adriamycin-induced nephrotic syndrome in rats. Lab Invest 46:16-23, 1982
134. NADASDY T, SILVA FG, HOGG RJ: Minimal change nephrotic syndrome-focal sclerosis complex (including IgM nephropathy and diffuse mesangial hypercellularity), in Renal Patholoy: With Clinical and Functional Correlations, edited by TISHER CC, BRENNER BM, Philadelphia, J.B. Lippincott Co, 1994, pp 330-389
135. SCHULZE M, DONADIO JV, PRUCHNO CJ, BAKER PJ, JOHNSON RJ, STAHL RAK, WATKINS S, MARTIN DC, WURZNER R, GOTZE O, COUSER WG: Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int 40:533-538, 1991
136. OGRADOWSKI JL, HERBERT LA, SEDMAK K, COSIO FG, TAMERIUS J, KOLB W: Measurement of C5b-9 in urine in patients with the nephrotic syndrome. Kidney Int 40:1141-1147, 1991
137. CAMUSSI G, TETTA C, MAZZUCCO G, VERCELLONE A: The brush border of proximal tubules of normal human kidney activates the alternative pathway of the complement system in vitro. Ann NY Acad Sci 420:321-324, 1983
138. OLSON JL, HOSTETTER TH, RENNKE HG, BRENNER BM, VENKATACHAKAM MA: Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. Kidney Int 22:112-126, 1982
139. WEN S-F, HUANG T-P, MOORTHY AV: Effects of low-protein diet on experimental diabetic nephropathy in the rat. J Lab Clin Med 106:589-597, 1985
140. WALKER JD, BENDING JJ, DODDS RA, MATTOCK MB, MURRELLS TJ, KEEN H, VIBERTI GC: Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 11:1411-1415, 1989
141. EL-NAHAS AM, MASTERS-THOMAS A, BRADY SA, FARRINGTON K, WILKINSON U, MILSON AJW, VARGHESE Z, MOORHEAD JF: Selective effect of low protein diets in chronic renal diseases. Br Med J 289:1337-1341, 1984
142. ROSMAN JB, TER WEE PM, MEIJER S, PIERS-BECHT TP, SLUTTER WJ, DONKER AJ: Prospective randomised trial of early dietary protein restriction in chronic renal failure. Lancet 2:1291-1296, 1984
143. KLAHR S, LEVEY AS, BECK GJ, CAGGIULA AW, HUNSICKER L, KUSEK JW, STRIKER G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330:877-884, 1994
144. REMUZZI A, PUNTORIERI S, BATTAGLIA C, BERTANI T, REMUZZI G: Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 85:541-549, 1990
145. ROSSING P, HOMMEL E, SMIDT UM, PARVING H-H: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 45(Suppl 45):S145-S149, 1994
146. BJORCK S, MULEC H, JOHNSEN SA, NORDEN G, AURELL M: Renal protective effect of enalapril in diabetic nephropathy. Br Med J 304:339-343, 1992
147. LEWIS EJ, HUNSICKER LG, BAIN RP ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
148. BREYER JA: Medical management of nephropathy in type I diabetes mellitus: Current recommendations. J Am Soc Nephrol 6:1523-1529, 1995
149. VIBERTI G, MOGENSEN CE, GROOP LC, PAULS JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 271:275-279, 1994
150. LAFFEL LMB, MCGILL JB, GANS DJ: The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 99:497-504, 1995
151. BAKRIS GL, COPLEY JB, VICKNAIR N: Blood pressure reduction and progression of diabetic nephropathy in atrican americans(AA): A five year follow-up, (abstract) J Am Soc Nephrol 6:446, 1995
152. BAKRIS GL, COPLEY JB, VICKNAIR N, LEURGANS S: Effect of nondihydropyridine calcium antagonists (NDCAs) on progression of nephropathy from noninsulin dependent diabetes (NIDDM). (abstract) J Am Soc Nephrol 6:446, 1995
153. RAVID M, LANG R, RACHMANI R, LISHNER M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 156:286-289, 1996
154. APPERLOO AJ, DE ZEEUW D, DE JOUG PE: The initial antiproteinuric effect of antihypertensive treatment predicts the effect of treatment on long-term renal function outcome. (abstract) J Am Soc Nephrol 3:279, 1992
155. PRAGA M, HERNANDEZ E, MONTOYO C, ANDRES A, RUILOPE LM, RODICIO JL: Long term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 20:240-248, 1992
156. KAMPER AL, STRAUDGAARD S, LEYSSAC PP: Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 5:423-430, 1992
157. HANNEDOUCHE T, LAUDAIS P, GOLDFARB B, EL ESPER N, FOURNIER A, GADIN M, DURAND D, CHENARD J, MIGNON F, SUE JM, GRIINFELD JP: Randomized controlled trial of enalapril and β blockers in non-diahetic chronic renal failure. Br Med J 309:833-837, 1994
158. MASCHIO G, ALBERTI D, JANIN G, LOCATELLI F, MANN JFE, MOTOLESE M, PONTICELLI C, RITZ E, ZUCCHELLI P, ACE INHIBITION IN PROGRESSIVE RENAL INSUFFICIENCY STUDY GROUP: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996
159. GANSEVOORT RT, SLUITER WJ, HEMMELDER MH, DE ZEEUW D, DE JONG PE: Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant 10: 1963-1974, 1995
160. DE JONG PE, ANDERSON S, DE ZEEUW D: Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: Will such treatments also help to improve renal function outome? J Am Soc Nephrol 3:1333-1341, 1993
161. SAWICKI PT: Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy. J Hypertens 13:933-938, 1995
162. PETERSON JC, ADLER S, BURKART JM, GREENE T, HEBERT LA, HUNSICKER LG, KING AJ, KLAHR S, MASSRY SG, SEIFTER JL: Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 123:754-762, 1995
163. KLAG MJ, WHELTON PK, RANDALL BL, NEATON JD, BRANCATI FL, FORD CE, SHULMAN NB, STAMLER J: Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18, 1996
164. ISEKI K, IKEMIYA Y, FUKIYAMA K: Blood pressure and risk of end-stage renal disease in a screened cohort. Kidney Int 49(Suppl 55):S69-S71, 1996
165. WEIDMANN P, SCHNEIDER M, BOHLEN L: Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated meta-analysis. Nephrol Dial Transplant 10(Suppl 9):39-45, 1995
166. KASISKE BL, KALIL RSN, JENNIE Z, LIAO M, KEANE WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118:129-138, 1993
167. BOHLEN L, DE COURTEN M, WEIDMANN P: Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 7:84S-92S, 1994
168. HEEG JE, DE JONG PE, VAN DER HEM GK, DE ZEEUW D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36:272-279, 1989